In the BioHarmony Drug Report Database

"Preview" Icon

Selpercatinib

Retevmo, Retsevmo (selpercatinib) is a small molecule pharmaceutical. Selpercatinib was first approved as Retevmo on 2020-05-08. It is used to treat non-small-cell lung carcinoma and thyroid neoplasms in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma and thyroid neoplasms. It is known to target proto-oncogene tyrosine-protein kinase receptor Ret. Retevmo’s patents are valid until 2038-10-10 (FDA).

 

Trade Name

 

Retsevmo
 

Common Name

 

selpercatinib
 

ChEMBL ID

 

CHEMBL4559134
 

Indication

 

non-small-cell lung carcinoma, thyroid neoplasms
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Selpercatinib structure rendering